- Home
- JAZZ
as 05-30-2025 4:00pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 7.3B | IPO Year: | 2007 |
| Target Price: | $181.85 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.51 | EPS Growth: | 49.21 |
| 52 Week Low/High: | $95.49 - $148.06 | Next Earning Date: | 05-06-2025 |
| Revenue: | $4,064,808,000 | Revenue Growth: | 5.76% |
| Revenue Growth (this year): | 5.92% | Revenue Growth (next year): | 4.22% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mulligan Seamus | JAZZ | Director | May 9 '25 | Buy | $99.93 | 101,621 | $9,993,081.71 | 99,900 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | May 1 '25 | Sell | $118.18 | 1,500 | $176,350.00 | 438,807 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Apr 1 '25 | Sell | $123.75 | 1,500 | $185,625.00 | 438,807 | |
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Mar 10 '25 | Sell | $138.41 | 2,403 | $332,604.52 | 79,621 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 7 '25 | Sell | $137.81 | 1,140 | $157,103.40 | 7,012 | |
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Mar 5 '25 | Sell | $139.11 | 7,080 | $981,297.72 | 79,621 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
StockStory
5 days ago
3 of Wall Street’s Favorite Stocks with Mounting Challenges
TipRanks
8 days ago
Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board
PR Newswire
9 days ago
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Argus Research
10 days ago
JAZZ: Raising target price to $122.00
StockStory
12 days ago
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
Simply Wall St.
16 days ago
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point
MT Newswires
17 days ago
Jazz Pharmaceuticals Insider Bought Shares Worth $9,993,082, According to a Recent SEC Filing
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.